R1 RCM (NASDAQ:RCM) Price Target Raised to $16.00

R1 RCM (NASDAQ:RCM) had its price target hoisted by Deutsche Bank Aktiengesellschaft from $14.00 to $16.00 in a research report released on Tuesday, Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the healthcare provider’s stock.

Several other equities analysts have also recently issued reports on the company. Citigroup raised R1 RCM from a neutral rating to a buy rating and set a $16.00 price objective for the company in a report on Wednesday, March 20th. Morgan Stanley reiterated an overweight rating and set a $17.00 price objective on shares of R1 RCM in a research note on Monday. Royal Bank of Canada restated an outperform rating and issued a $19.00 price target on shares of R1 RCM in a research report on Friday, June 28th. Cantor Fitzgerald restated an overweight rating and issued a $20.00 price target on shares of R1 RCM in a research report on Tuesday, July 2nd. Finally, Guggenheim decreased their price objective on R1 RCM from $17.00 to $15.00 and set a buy rating on the stock in a report on Friday, April 5th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Moderate Buy and an average price target of $16.00.

R1 RCM Trading Down 3.3 %

Shares of NASDAQ:RCM opened at $12.49 on Tuesday. R1 RCM has a 12-month low of $8.87 and a 12-month high of $18.70. The business’s fifty day simple moving average is $12.41 and its 200-day simple moving average is $11.96. The company has a market capitalization of $5.26 billion, a PE ratio of -156.13 and a beta of 0.85. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78.

R1 RCM (NASDAQ:RCM) last posted its quarterly earnings data on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The business had revenue of $603.90 million during the quarter, compared to analyst estimates of $612.88 million. R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. R1 RCM’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, equities research analysts predict that R1 RCM will post -0.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On R1 RCM

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of R1 RCM by 5.6% during the third quarter. Vanguard Group Inc. now owns 17,940,792 shares of the healthcare provider’s stock worth $270,368,000 after purchasing an additional 947,310 shares during the last quarter. Capital International Investors lifted its position in R1 RCM by 0.8% in the fourth quarter. Capital International Investors now owns 8,343,199 shares of the healthcare provider’s stock valued at $88,188,000 after purchasing an additional 67,485 shares during the period. Voss Capital LLC lifted its position in shares of R1 RCM by 553.9% during the 4th quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock valued at $75,311,000 after acquiring an additional 6,035,340 shares during the period. Norges Bank acquired a new stake in shares of R1 RCM during the 4th quarter valued at approximately $42,539,000. Finally, P2 Capital Partners LLC lifted its position in shares of R1 RCM by 70,366.3% during the 4th quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock valued at $37,368,000 after acquiring an additional 3,530,277 shares during the period. Hedge funds and other institutional investors own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.